Magic mushrooms may ‘reset’ the brains of depressed patients

  Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a ‘reset’ of their brain activity. …     The findings come from a study in which researchers from Imperial College London used psilocybin – the psychoactive compound that occurs naturally in magic mushrooms – to treat a small number of …

Read moreMagic mushrooms may ‘reset’ the brains of depressed patients

Risky research could herald mindful revolution

  Pioneering research into psychedelic drugs could herald a revolution in our understanding of human consciousness and how we treat mental illness.       With its roots in the great age of Victorian invention, Imperial College London looks back on a rich heritage of breakthroughs in science, engineering and medicine – from the discovery …

Read moreRisky research could herald mindful revolution

Psychedelic expert: Shrooms will be approved for depression in 10 years

Ask a healthy person who’s tripped on psychedelics what it felt like, and they’ll probably tell you they saw sounds or heard colors: The crash-bang of a dropped box took on an aggressive,dark shape. A bright green light seemed to emit a piercing, high-pitched screech. In actuality, this “cross-wiring” — synaesthesia, as it’s known scientifically — may …

Read morePsychedelic expert: Shrooms will be approved for depression in 10 years

LSD enhances the emotional response to music

Rationale There is renewed interest in the therapeutic potential of psychedelic drugs such as lysergic acid diethylamide LSD). LSD was used extensively in the 1950s and 1960s as an adjunct in psychotherapy, reportedly enhancing emotionality. Music is an effective tool to evoke and study emotion and is considered an important element in psychedelic-assisted psychotherapy; however, …

Read moreLSD enhances the emotional response to music

Psychedelic drugs should be legally reclassified

Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential Trials of physiologically safe and non-addictive drugs such as LSD are almost impossible, writes James J H Rucker, calling on the authorities to downgrade their unnecessarily restrictive class A, schedule 1 classification James J H Rucker specialist registrar in adult psychiatry …

Read morePsychedelic drugs should be legally reclassified

The Trip Treatment – The New Yorker

Psilocybin may be useful in treating anxiety, addiction, and depression, and in studying the neurobiology of mystical experience.

Extract from The Trip Treatment – The New Yorker

On an April Monday in 2010, Patrick Mettes, a fifty-four-year-old television news director being treated for a cancer of the bile ducts, read an article on the front page of the Times that would change his death. His diagnosis had come three years earlier, shortly after his wife, Lisa, noticed that the whites of his eyes had turned yellow. By 2010, the cancer had spread to Patrick’s lungs and he was buckling under the weight of a debilitating chemotherapy regimen and the growing fear that he might not survive. The article, headlined “Hallucinogens Have Doctors Tuning in Again,” mentioned clinical trials at several universities, including N.Y.U., in which psilocybin—the active ingredient in so-called magic mushrooms—was being administered to cancer patients in an effort to relieve their anxiety and “existential distress.” One of the researchers was quoted as saying that, under the influence of the hallucinogen, “individuals transcend their primary identification with their bodies and experience ego-free states . . . and return with a new perspective and profound acceptance.” Patrick had never taken a psychedelic drug, but he immediately wanted to volunteer. Lisa was against the idea. “I didn’t want there to be an easy way out,” she recently told me. “I wanted him to fight.”

The revival of psychedelic research today owes much to the respectability of its new advocates. At sixty-eight, Roland Griffiths, who was trained as a behaviorist and holds senior appointments in psychiatry and neuroscience at Hopkins, is one of the nation’s leading drug-addiction researchers. More than six feet tall, he is rail-thin and stands bolt upright; the only undisciplined thing about him is a thatch of white hair so dense that it appears to have held his comb to a draw. His long, productive relationship with nida has resulted in some three hundred and fifty papers, with titles such as “Reduction of Heroin Self-Administration in Baboons by Manipulation of Behavioral and Pharmacological Conditions.” Tom Insel, the director of the N.I.M.H., described Griffiths as “a very careful, thoughtful scientist” with “a reputation for meticulous data analysis. So it’s fascinating that he’s now involved in an area that other people might view as pushing the edge.”

The lab at Hopkins is currently conducting a study of particular interest to Griffiths: examining the effect of psilocybin on long-term meditators. The study plans to use fMRI—functional magnetic-resonance imaging—to study the brains of forty meditators before, during, and after they have taken psilocybin, to measure changes in brain activity and connectivity and to see what these “trained contemplatives can tell us about the experience.” Griffiths’s lab is also launching a study in collaboration with N.Y.U. that will give the drug to religious professionals in a number of faiths to see how the experience might contribute to their work. “I feel like a kid in a candy shop,” Griffiths told me. “There are so many directions to take this research. It’s a Rip Van Winkle effect—after three decades of no research, we’re rubbing the sleep from our eyes.”

“Ineffability” is a hallmark of the mystical experience. Many struggle to describe the bizarre events going on in their minds during a guided psychedelic journey without sounding like either a New Age guru or a lunatic. The available vocabulary isn’t always up to the task of recounting an experience that seemingly can take someone out of body, across vast stretches of time and space, and include face-to-face encounters with divinities and demons and previews of their own death.

Volunteers in the N.Y.U. psilocybin trial were required to write a narrative of their experience soon after the treatment, and Patrick Mettes, having worked in journalism, took the assignment seriously. His wife, Lisa, said that, after his Friday session, he worked all weekend to make sense of the experience and write it down.

When Mettes arrived at the treatment room, at First Avenue and Twenty-fifth Street, Tony Bossis and Krystallia Kalliontzi, his guides, greeted him, reviewed the day’s plan, and, at 9 A.M., presented him with a small chalice containing the pill. None of them knew whether it contained psilocybin or the placebo. Asked to state his intention, Mettes said that he wanted to learn to cope better with the anxiety and the fear that he felt about his cancer. As the researchers had suggested, he’d brought a few photographs along—of Lisa and him on their wedding day, and of their dog, Arlo—and placed them around the room.

Read moreThe Trip Treatment – The New Yorker

Magic mushrooms ‘less harmful than thought’ , says leading psychiatrist

Researchers are beginning to look again at how LSD and psilocybin – the active compound in magic mushrooms – might be of benefit in the treatment of addiction, for obsessive compulsive disorder and even, according to one small Swiss study, to alleviate the symptoms of anxiety in terminally ill patients.

However, writing in the BMJ, psychiatrist Dr James Rucker, said that no evidence had ever shown the drugs to be habit-forming. There is also little evidence of harm when used in controlled settings, and a wealth of studies indicating that they have uses in the treatment of common psychiatric disorders, he said.

 Curated from Magic mushrooms ‘less harmful than thought’ and should be reclassified, says leading psychiatrist – Health News – Health & Families – The Independent

LSD cures depression? Scientists plead for cash to fund ‘exciting’ drug study

The study, carried out as part of a psychedelic research project by neuroscientists at Imperial College London, is expected to “revolutionize” scientists understanding of the brain.

To date, the project has been partially funded by Imperial College London and the Beckley Foundation. However, researchers are now in need of £25,000 to analyze scans.